Approval · Notice of Compliance 3526 · 2003
DIOVAN: Notice of Compliance 3526
Issued December 15, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3526
- Date
- December 15, 2003
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update the product monograph to include a statement that administration of valsartan to patients with type ii diabetes and microalbuminuria has resulted in significant reduction of urinary albumin excretion
- Therapeutic class
- Angiotensin ii at1 receptor blocker
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| DIOVAN | Not yet assigned | — |